Primo N. Lara
- Pulmonary and Respiratory Medicine top 0.05%
- Lung Cancer Treatments and Mutations 125
- Prostate Cancer Treatment and Research 98
- Renal cell carcinoma treatment 78
- Oncology top 0.2%
- Lung Cancer Research Studies 69
- Peptidase Inhibition and Analysis 36
- Cancer Research top 0.2%
- Cancer Genomics and Diagnostics 82
- Hematology top 1%
- Molecular Biology top 0.5%
-
- Bladder and Urothelial Cancer Treatments 47
-
- Radiopharmaceutical Chemistry and Applications 38
- Co-authors
- David R. GandaraPhilip C. MackMaha HussainCatherine M. TangenDaniel P. PetrylakEric J. SmallPatrick A. BurchE. David Crawford
- Journals
- New England Journal of Medicine (1 paper)The Lancet (2 papers)Journal of Clinical Oncology (188 papers)
- Partner nations
- United StatesCanadaFrance
In The Last Decade
Primo N. Lara
443 papers receiving 15.9k citations
Hit Papers
Peers
Comparison fields: 5 of 157
- Pulmonary and Respiratory Medicine 8.5k
- Oncology 7.0k
- Cancer Research 3.5k
- Hematology 986
- Molecular Biology 6.0k
Countries citing papers authored by Primo N. Lara
This map shows the geographic impact of Primo N. Lara's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Primo N. Lara with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Primo N. Lara more than expected).
Fields of papers citing papers by Primo N. Lara
This network shows the impact of papers produced by Primo N. Lara. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Primo N. Lara. The network helps show where Primo N. Lara may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Primo N. Lara, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 2 | |
| 2 | 2024 | 1 | |
| 3 | 2024 | 1 | |
| 4 | 2023 | 5 | |
| 5 | 2023 | 4 | |
| 6 | 2022 | 30 | |
| 7 | 2019 | 40 | |
| 8 | 2019 | 116 | |
| 9 | 2019 | 19 | |
| 10 | 2018 | 4 | |
| 11 | 2017 | 36 | |
| 12 | 2016 | 20 | |
| 13 | 2015 | 66 | |
| 14 | 2013 | 22 | |
| 15 | 2012 | 34 | |
| 16 | 2011 | 17 | |
| 17 | 2009 | 64 | |
| 18 | 2008 | 67 | |
| 19 | 2006 | 19 | |
| 20 | SU5416 plus interferon alpha in advanced renal cell carcinoma: a phase II California Cancer Consortium Study with biological and imaging correlates of angiogenesis inhibition. | 2003 | 51 |
About Primo N. Lara
Primo N. Lara is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research, having authored 458 papers that have together received 16.3k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (125 papers), Prostate Cancer Treatment and Research (98 papers), Cancer Genomics and Diagnostics (82 papers), Renal cell carcinoma treatment (78 papers), Lung Cancer Research Studies (69 papers), Bladder and Urothelial Cancer Treatments (47 papers), Radiopharmaceutical Chemistry and Applications (38 papers) and Peptidase Inhibition and Analysis (36 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (8.5k citations), Oncology (7.0k citations) and Cancer Research (3.5k citations). Primo N. Lara has collaborated with scholars based in United States, Canada and France. Frequent co-authors include David R. Gandara, Philip C. Mack, Maha Hussain, Catherine M. Tangen, Daniel P. Petrylak, Eric J. Small, Patrick A. Burch, E. David Crawford, Mary Ellen Taplin and Carol M. Moinpour. Their work appears in journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.